Livforsakringsbolaget Skandia Omsesidigt Sells 10,700 Shares of Eli Lilly And Co (LLY)

Livforsakringsbolaget Skandia Omsesidigt lessened its holdings in Eli Lilly And Co (NYSE:LLY) by 36.7% during the third quarter, HoldingsChannel.com reports. The firm owned 18,417 shares of the company’s stock after selling 10,700 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Eli Lilly And Co were worth $1,976,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in LLY. Morgan Stanley grew its holdings in Eli Lilly And Co by 37.8% in the second quarter. Morgan Stanley now owns 4,473,537 shares of the company’s stock worth $381,727,000 after purchasing an additional 1,227,888 shares during the period. BlackRock Inc. lifted its stake in shares of Eli Lilly And Co by 1.3% in the second quarter. BlackRock Inc. now owns 66,644,897 shares of the company’s stock worth $5,686,808,000 after buying an additional 864,451 shares in the last quarter. Investec Asset Management LTD lifted its stake in shares of Eli Lilly And Co by 49.6% in the second quarter. Investec Asset Management LTD now owns 2,528,279 shares of the company’s stock worth $215,738,000 after buying an additional 838,271 shares in the last quarter. Smith Asset Management Group LP bought a new position in shares of Eli Lilly And Co in the second quarter worth approximately $65,407,000. Finally, Unigestion Holding SA bought a new position in shares of Eli Lilly And Co in the second quarter worth approximately $64,279,000. Institutional investors and hedge funds own 76.35% of the company’s stock.

Several research analysts have recently issued reports on LLY shares. SunTrust Banks upped their target price on shares of Eli Lilly And Co from $105.00 to $123.00 and gave the stock a “buy” rating in a research note on Monday, October 1st. Zacks Investment Research downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Friday, September 28th. TheStreet downgraded shares of Eli Lilly And Co from a “b” rating to a “c+” rating in a research note on Friday, August 24th. Cantor Fitzgerald reiterated a “buy” rating and issued a $128.00 target price on shares of Eli Lilly And Co in a research note on Wednesday, October 17th. Finally, JPMorgan Chase & Co. set a $117.00 target price on shares of Eli Lilly And Co and gave the stock an “overweight” rating in a research note on Wednesday, September 26th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Eli Lilly And Co has a consensus rating of “Buy” and a consensus price target of $111.53.



In related news, SVP Alfonso G. Zulueta sold 6,000 shares of the stock in a transaction that occurred on Tuesday, September 18th. The shares were sold at an average price of $106.31, for a total transaction of $637,860.00. Following the transaction, the senior vice president now owns 55,224 shares in the company, valued at $5,870,863.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Donald A. Zakrowski sold 600 shares of the stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $105.57, for a total transaction of $63,342.00. Following the transaction, the insider now owns 3,530 shares in the company, valued at approximately $372,662.10. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,775,271 shares of company stock worth $182,924,902. 0.11% of the stock is owned by insiders.

Shares of Eli Lilly And Co stock opened at $106.39 on Friday. The company has a market cap of $115.87 billion, a P/E ratio of 21.45, a P/E/G ratio of 1.75 and a beta of 0.29. Eli Lilly And Co has a twelve month low of $73.69 and a twelve month high of $116.61. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.09 and a current ratio of 1.40.

Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 24th. The company reported $1.50 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.30 by $0.20. The company had revenue of $6.36 billion for the quarter, compared to the consensus estimate of $6.05 billion. Eli Lilly And Co had a negative net margin of 0.60% and a positive return on equity of 39.84%. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.11 earnings per share. On average, research analysts anticipate that Eli Lilly And Co will post 5.47 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 10th. Investors of record on Thursday, November 15th will be given a dividend of $0.5625 per share. The ex-dividend date of this dividend is Wednesday, November 14th. This represents a $2.25 dividend on an annualized basis and a yield of 2.11%. Eli Lilly And Co’s dividend payout ratio (DPR) is 52.57%.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: What are the economic characteristics of a bear market?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply